Basis of Presentation and Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2025

Basis of Presentation and Summary of Significant Accounting Policies [Abstract]

The following table provides a reconciliation of the components of cash, cash equivalents and restricted cash reported in the Company’s consolidated balance sheets to the total of the amount presented in the consolidated statements of cash flows (in thousands):

	December 31,
	2025		2024

Cash and cash equivalents	$	7,912	$	7,261
Restricted cash		—		1,334
Total cash, cash equivalents and restricted cash presented in the consolidated statements of cash flows	$	7,912	$	8,595

Allowance for Credit Losses

The activity in the allowance for credit losses is summarized as follows (in thousands):

	December 31,
	2025			2024

Balance, beginning of year	$	433		$	222
Provision for expected losses		134			(179	)
Write-offs charged against the allowance		(16	)		141
Other adjustments		—			249
Balance, end of year	$	551		$	433

Accrued Warranty Costs Activity

The activity in the warranty accrual during the years ended December 31, 2025 and 2024 is summarized as follows (in thousands):

	December 31,
	2025			2024

Balance, beginning of year	$	315		$	303
Additions		100			156
Expirations and claims satisfied		(195	)		(144	)
Total		220			315
Less current portion within accrued expenses and other current liabilities		(157	)		(213	)
Balance within deferred revenues and other liabilities	$	63		$	102

Disaggregation of Revenue

The following table presents the Company’s net revenues disaggregated by dermatology recurring procedures and dermatology procedures equipment (in thousands):

	Year Ended December 31,
	2025		2024

Dermatology recurring procedures	$	21,478	$	21,171
Dermatology procedures equipment		9,218		12,391
Total net revenues	$	30,696	$	33,562

Future Undiscounted Fixed Treatment Code Payments from International Dermatology Recurring Procedures

The following table summarizes the Company’s expected future undiscounted fixed treatment code payments from international dermatology recurring procedures, the Company’s only long-term arrangements, as of December 31, 2025 (in thousands):

Years ending December 31:
2026	$	1,983
2027		1,798
2028		1,236
2029		266
	$	5,283

Antidilutive Securities Excluded from Computation of Net Loss Per Share

The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:

	December 31,
	2025		2024

Stock options		725,726		521,726
Common stock warrants		80,000		80,000
Restricted stock units		2,265		2,265
		807,991		603,991